Biobusiness Briefs | Published:

Market watch

Innovation in the preclinical antibiotic pipeline

Nature Reviews Drug Discovery volume 16, pages 744745 (2017) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


U.T, M.S. and C.Å. were partly supported by the Innovative Medicines Initiative Joint Undertaking DRIVE-AB grant number 115583; M.S. and C.Å. are partly funded by the Norwegian Research Council (grant number 234608); K.O. is supported by the Cooperative Agreement Number 6 IDSEP160030-02-01from the Biomedical Advanced Research and Development Authority (BARDA) and by an award from the Wellcome Trust. CARB-X is also supported by the National Institute of Allergy and Infectious Diseases. This article is solely the responsibility of the authors and does not necessarily represent the official views of The Assistant Secretary for Preparedness and Response, the National Institutes of Health, the Wellcome Trust, DRIVE-AB or the Innovative Medicines Initiative.

Author information


  1. Center for Anti-Infective Agents, Eckpergasse 13, 1180 Vienna, Austria

    • Ursula Theuretzbacher
  2. Norwegian Institute of Public Health, PO Box 4404 Nydalen N-0403 Oslo, Norway

    • Miloje Savic
    •  & Christine Årdal
  3. Boston University School of Law, Boston, Massachusetts 02215, USA and CARB-X.

    • Kevin Outterson


  1. Search for Ursula Theuretzbacher in:

  2. Search for Miloje Savic in:

  3. Search for Christine Årdal in:

  4. Search for Kevin Outterson in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Ursula Theuretzbacher.

About this article

Publication history



Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing